Cryofocus Medtech (Shanghai) Co (HKSE:06922) Long-Term Capital Lease Obligation : HK$7.95 Mil (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Long-Term Capital Lease Obligation?

Cryofocus Medtech (Shanghai) Co's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was HK$7.95 Mil.

Cryofocus Medtech (Shanghai) Co's quarterly Long-Term Capital Lease Obligation increased from Jun. 2022 (HK$0.00 Mil) to Dec. 2022 (HK$8.87 Mil) but then declined from Dec. 2022 (HK$8.87 Mil) to Jun. 2023 (HK$7.95 Mil).

Cryofocus Medtech (Shanghai) Co's annual Long-Term Capital Lease Obligation increased from Dec. 2020 (HK$0.15 Mil) to Dec. 2021 (HK$7.84 Mil) and increased from Dec. 2021 (HK$7.84 Mil) to Dec. 2022 (HK$8.87 Mil).

Cryofocus Medtech (Shanghai) Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Long-Term Capital Lease Obligation Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

0.15

7.84

8.87

8.49

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial			7.84	-	8.87	7.95	8.49

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Cryofocus Medtech (Shanghai) Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines